<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173053</url>
  </required_header>
  <id_info>
    <org_study_id>NL 61885.091.17</org_study_id>
    <nct_id>NCT03173053</nct_id>
  </id_info>
  <brief_title>S. Aureus Decolonization in HPN Patients.</brief_title>
  <acronym>CARRIER</acronym>
  <official_title>Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial focusses on identifying the most effective and safe long-term S. aureus carriage
      decolonization strategy in home parenteral nutrition patients. Half of the participants will
      receive a quick and short systemic antibiotic treatment combined with topical treatment,
      while the other half will receive only topical treatment on a periodic basis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients on home parenteral nutrition (HPN) are exposed to a lifelong risk of developing S.
      aureus bacteremia (SAB). SAB pose a threat to both catheter and patient survival and may lead
      to a permanent loss of vascular access. S. aureus carriage eradication has proven successful
      in prevention of S. aureus infections. S. aureus decolonization is a key strategy to maintain
      venous access and avoid hospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">August 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized controlled, open label superiority trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients totally eradicated for S. aureus during one year</measure>
    <time_frame>One year</time_frame>
    <description>Totally eradicated is defined as 100% of all culture swabs (nose, throat, rectum), exit-site catheter and body regions on indication) being negative for S. aureus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients totally eradicated after one year</measure>
    <time_frame>One year</time_frame>
    <description>Proportion of patients totally eradicated for S. aureus based on negative cultures performed after one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developing long-term antimicrobial resistance</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Long-term antimicrobial resistance at 6 and 12 months (measured with standard cultures and NGS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of S. aureus infections</measure>
    <time_frame>Every 3 months during one year</time_frame>
    <description>Incidence of S. aureus infections measured with (serious) adverse events forms every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of infections</measure>
    <time_frame>Every three months during one year</time_frame>
    <description>Overall incidence and time to onset of infections measured with (serious) adverse events forms every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of catheter removals</measure>
    <time_frame>One year</time_frame>
    <description>Number of catheter removals based on data from electronic patient dossier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>One year</time_frame>
    <description>Mortality based on data from electronic patient dossier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S. aureus transmission</measure>
    <time_frame>One year</time_frame>
    <description>S. aureus transmission routes from caregiver to patient (measured with NGS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>Every three months during one year</time_frame>
    <description>Patient compliance (measured with medication files, counting pills, trial-specific medication diary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Every three months during one year</time_frame>
    <description>Adverse events (measured with (serious) adverse event forms every 3 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for infections and treatment outcome</measure>
    <time_frame>One year</time_frame>
    <description>Predictors for infections and treatment failure/success (binominal regression analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>0, 6 and 12 months</time_frame>
    <description>Generic health related quality of life (measured with a validated questionnaire (EQ5D-5L)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare related costs.</measure>
    <time_frame>One year</time_frame>
    <description>Cost-effectiveness analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <condition>Motility Disorder</condition>
  <arm_group>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.
Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous suppression (CS) strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A repeated, continuous, topical decolonization treatment of S. aureus
Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole/trimethoprim</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
    <other_name>Bactrimel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fusidic Acid</intervention_name>
    <description>tablet or ointment</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>tablet</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>Mouthwash or bodywash</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
    <arm_group_label>Continuous suppression (CS) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin</intervention_name>
    <description>Nasal ointment</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
    <arm_group_label>Continuous suppression (CS) strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betadine</intervention_name>
    <description>Shampoo</description>
    <arm_group_label>Search and destroy (SD) strategy</arm_group_label>
    <arm_group_label>Continuous suppression (CS) strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is fully able to understand the nature of the proposed intervention.

          -  Written informed consent by the patient before entering the trial.

          -  Age ≥ 18 years.

          -  Estimated life expectancy ≥ 1 year.

          -  Patient colonized with S. aureus.

        Exclusion Criteria:

          -  Cannot be expected to comply with the trial plan (substance abuse, mental condition).

          -  Pregnant or breastfeeding women.

          -  Continuous exposure to Methicillin-resistant S. aureus (MRSA; e.g. pig farmer).

          -  Allergy for chlorhexidine and betadine.

          -  No options for oral and/or topical antibiotics due to allergies.

          -  Active S. aureus infection.

          -  Currently on treatment with antibiotics active against S. aureus.

          -  Decolonization (including mupirocin) treatment in the previous two months.

          -  The presence of a nasal foreign body.

          -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels more than
             five times the upper limit of normal or liver failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost PH Drenth, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Gompelman, MD</last_name>
    <phone>0031611847365</phone>
    <phone_ext>0031653523983</phone_ext>
    <email>michelle.gompelman@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geert JA Wanten, MD, PhD</last_name>
    <phone>0031243614760</phone>
    <email>geert.wanten@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Henrik Rasmussen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Palle B Jeppesen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michelle Gompelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>100DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>M J Serlie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S. aureus</keyword>
  <keyword>Home Parenteral Nutrition</keyword>
  <keyword>Intestinal failure</keyword>
  <keyword>Eradication</keyword>
  <keyword>Decolonization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
    <mesh_term>Fusidic Acid</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

